Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability

Archives of Neurology

Volumn 58, Issue 1, 2001, Pages 65-70

  De Stefano, N ^a   Narayanan, S ^a   Francis, G S ^a   Arnaoutelis, R ^a   Tartaglia, M C ^a   Antel, J P ^a   Matthews, P M ^a   Arnold, D L ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; AXONAL INJURY; CONTROLLED STUDY; DISABILITY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 0035166271     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.58.1.65     Document Type: Article

References (53)

1. Rachelle Fishman-Matthew Moore Lecture: The pathological and clinical dynamics of multiple sclerosis
2. Putting magnetic resonance spectroscopy studies in context: Axonal damage and disability in multiple sclerosis
3. Axonal pathology in multiple sclerosis: Relationship to neurological disability
4. Multiple sclerosis as a neuronal disease
5. Axonal damage in acute multiple sclerosis lesions
6. Axonal transection in the lesions of multiple sclerosis
7. Axonal degeneration in the pathogenesis of multiple sclerosis
8. The longstanding MS lesion: A quantitative MRI and electron microscopic study
9. Axon loss in multiple sclerosis
10. N-acetyl-L-aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain
11. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies
12. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease
13. Chemical pathology of acute demyelinating lesions and its correlation with disability
14. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss
15. Imaging axonal damage of normal-appearing white matter in multiple sclerosis
16. Axonal damage correrates with disability in patients with relapsing-remitting multiple sclerosis: Results of a longitudinal magnetic resonance spectroscopy study
17. Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup?
18. Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis
19. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
20. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS)
21. Reversible decreases in N-acetylaspartate after acute brain injury
22. 1H NMR chemical shift selective (CHESS) imaging
23. 1H NMR spectroscopic imaging
24. 1H spectroscopic imaging data sets
25. High resolution proton NMR spectroscopy of multiple sclerosis lesions
26. Demyelination: The role of reactive oxygen and nitrogen species
27. Increase of sodium channels in demyelinated lesions of multiple sclerosis
28. Distribution of sodium channels in chronically demyelinated spinal cord axons: Immuno-ultrastructural localization and electrophysiological observations
29. Molecular remodeling of neurons in multiple sclerosis: What we know, and what we must ask about brain plasticity in demyelinating diseases
30. Relating axonal injury to functional recovery in MS
31. Proton magnetic resonance spectroscopy in a pathologically confirmed acute demyelinating lesion
32. Axonal cytoskeleton changes in experimental optic neuritis
33. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions
34. Neurodegeneration in multiple sclerosis: Relationship to neurological disability
35. A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis
36. Measures of brain and spinal cord atrophy in multiple sclerosis
37. Spinal cord atrophy and disability in MS: A longitudinal study
38. Brain and spinal cord abnormalities in multiple sclerosis: Correlation between MRI parameters, clinical subtypes and symptoms
39. A longitudinal study of brain atrophy in relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group (MSCRG)
40. Immunohistochemical localization of N-acetylaspartate in rat brain
41. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types
42. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis
43. In vitro expression of N-acetyl aspartate by oligodendrocytes: Implications for proton magnetic resonance spectroscopy signal in vivo
44. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells
45. 1H spectroscopic imaging
46. 1H spectroscopic imaging at 4.1 T
47. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis
48. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients
49. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy
50. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis
51. Total brain N-acetylaspartate: A new measure of disease load in MS
52. Future options for therapies to limit damage and enhance recovery
53. Eliprodil stimulates CNS myelination: New prospects for multiple sclerosis?